T cell tumours of disparate phenotype in mice transgenic for Rbtn-2.
RBTN2 is a LIM domain protein which can be activated by the translocation t(11;14)(p13;q11) in childhood T cell acute leukaemia. Transgenic mice were examined in which rbtn2 protein is expressed in the T cell lineage. An average of 72% of these mice developed T cell tumours before 18 months of age, compared with 9% in transgenic mice expressing the related gene Rbtn-1. Rbtn2-induced tumours first appeared at 5 months of age and were clonal. They displayed a range of phenotypes, the most notable being CD3/CD45R double-positive cells. Tumours expressing either T cell receptor alpha/beta or gamma/delta heterodimers were found. Thus rbtn2 can promote tumours within a range of T cell types and maturities. The latency period before tumour development indicates that secondary events must occur before the onset of overt malignancy.
Larson
R C
RC
MRC Laboratory of Molecular Biology, Cambridge, UK.
Fisch
P
P
Larson
T A
TA
Lavenir
I
I
Langford
T
T
King
G
G
Rabbitts
T H
TH
D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D018801:CD2 Antigens / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D060588:LIM Domain Proteins; D016399:Lymphoma, T-Cell / Q000235:genetics* / Q000473:pathology; D008667:Metalloproteins / Q000235:genetics*; D051379:Mice; D008822:Mice, Transgenic; D009361:Neoplasm Invasiveness; D010641:Phenotype; D014178:Translocation, Genetic
D048868:Adaptor Proteins, Signal Transducing; D018801:CD2 Antigens; D004268:DNA-Binding Proteins; D060588:LIM Domain Proteins; C513188:Lmo2 protein, mouse; D008667:Metalloproteins